Drug analysis: Farxiga

Drug analysis: Farxiga

  • December 2017 •
  • 41 pages •
  • Report ID: 5336378 •
  • Format: PDF
Drug Overview
Farxiga (dapagliflozin; AstraZeneca) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. It is approved for the treatment of type 2 diabetes and currently in Phase III trials for the treatment of type 1 diabetes.

SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism. They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion. Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy, they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia.

The drug was developed as part of a joint venture between AstraZeneca and Bristol-Myers Squibb. However, AstraZeneca has taken full ownership and marketing responsibilities after buying its partner’s share of the venture.